Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fupu Ganmao granules for influenza (wind-heat attacking defense syndrome) phase II trial
CTR20254989Phase 2Completed
- Sponsor
- Zhejiang Tianyitang Pharmaceutical
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fupu Ganmao Granules in influenza (3 arms), sponsored by Zhejiang Tianyitang Pharmaceutical. Primary endpoint: Time to symptom relief. Started Dec 2025; status: completed.
02
Drugs
Fupu Ganmao Granules
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20254989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254989.